The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib
Open Access
- 9 January 2025
- journal article
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 8, 100212
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (8247131137)
- National Natural Science Foundation of China (81773765)
This publication has 45 references indexed in Scilit:
- Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB /IL-6/STAT3 and JNK/PTX3 pathwaysActa Pharmaceutica Sinica B, 2022
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progressionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Sphingosine-1-phosphate receptor 3 signalingClinica Chimica Acta, 2021
- The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapyPharmacology & Therapeutics, 2019
- Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cellsCell Death Discovery, 2017
- SOCS1 in cancer: An oncogene and a tumor suppressorCytokine, 2016
- Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543Biochemical and Biophysical Research Communications, 2016
- Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancerCancer Immunology, Immunotherapy, 2011
- Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancerBreast Cancer Research and Treatment, 2007